Activated protein C resistance assay when applied in the general population.
We estimated the predictive values of activated protein C resistance in the diagnosis of women who are carriers of factor V Leiden. When the prevalence of factor V Leiden is 2%, the positive predictive value is 44% and the cost of preventing one thromboembolic death is $44,180,000. Thus the activated protein C resistance assay is not cost-effective in ruling out factor V Leiden in this population.
Altès
A
A
Department of Hematology, Hospital de la Santa Creu I Sant Pau de Barcelona, Spain.
Souto
J C
JC
Mateo
J
J
Borrell
M
M
Fontcuberta
J
J
D001499:Bayes Theorem; D003276:Contraceptives, Oral / Q000008:administration & dosage; D003362:Cost-Benefit Analysis / Q000191:economics; D004351:Drug Resistance / Q000235:genetics; D005165:Factor V / Q000032:analysis*; D005260:Female; D006579:Heterozygote; D006801:Humans; D008403:Mass Screening; D011237:Predictive Value of Tests; D011486:Protein C; D011933:Reagent Kits, Diagnostic / Q000191:economics; D013927:Thrombosis / Q000191:economics / Q000235:genetics / Q000517:prevention & control*
D003276:Contraceptives, Oral; D011486:Protein C; D011933:Reagent Kits, Diagnostic; C095381:factor V Leiden; D005165:Factor V